

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/378856850>

Drug–Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes

Article · March 2024

CITATIONS

0

READS

7

4 authors, including:



Emmanuel Ifeanyi Obeagu

Kampala International University (KIU)

1,422 PUBLICATIONS 11,224 CITATIONS

[SEE PROFILE](#)



Getrude Uzoma Obeagu

Kampala International University (KIU)

384 PUBLICATIONS 3,307 CITATIONS

[SEE PROFILE](#)

Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes

*Emmanuel Ifeanyi Obeagu¹, Ebere Emilia Ayogu^{2,3}, Chinyere Nkemjika Anyanwu⁴ and Getrude Uzoma Obeagu⁵

¹Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.

²Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria.

³Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy, Kampala International University, Western Campus, Uganda

⁴Department of Microbiology and Immunology, Kampala International University, Western Campus, Uganda

⁵School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

This review scrutinizes the intricate landscape of drug-drug interactions in the management of coexisting sickle cell anemia and diabetes, two chronic conditions that often intersect, challenging healthcare providers in their pursuit of optimal patient care. Sickle cell anemia, a hereditary hemoglobinopathy, and diabetes, a metabolic disorder, present a complex interplay that requires careful consideration of treatment strategies and potential interactions between medications prescribed for both conditions. This abstract encapsulates the essence of the review, emphasizing the need for a thorough understanding of drug interactions to ensure effective management and improved outcomes in individuals navigating the challenging intersection of sickle cell anemia and diabetes.

Keywords: *drug-drug interactions, sickle cell anemia, diabetes*

Introduction

The landscape of healthcare is marked by the convergence of diverse medical conditions, each presenting its unique challenges and complexities. Among the intersections that demand
Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science, 2024; 2(2):1-9

meticulous attention is the coexistence of sickle cell anemia and diabetes, two chronic conditions with distinct pathophysiological mechanisms. Sickle cell anemia, a hereditary hemoglobinopathy, and diabetes, a metabolic disorder, together pose a formidable clinical scenario, necessitating a comprehensive understanding of their shared complexities and the potential interactions between their respective treatment regimens. Sickle cell anemia, characterized by the presence of abnormal hemoglobin, results in the deformation of red blood cells, leading to vaso-occlusive events and tissue damage. Concurrently, diabetes, marked by impaired insulin function and glucose metabolism, poses additional challenges related to vascular complications and heightened susceptibility to infections. The interplay between these conditions is a dynamic field, and their coexistence presents a unique set of therapeutic considerations, particularly concerning the potential drug-drug interactions when managing both conditions simultaneously.¹⁻²³

The unique challenges in diabetes care for individuals with sickle cell anemia add an additional layer of complexity to the management paradigm. Diabetes, itself a chronic condition requiring meticulous management, intersects with the complications and complexities of sickle cell anemia, demanding a holistic and integrated approach. The synergy between diabetes and sickle cell anemia raises questions about potential synergistic effects on disease progression, complications, and overall patient outcomes. Addressing the challenges in diabetes care for individuals with sickle cell anemia involves navigating the intricate web of pathophysiological mechanisms, therapeutic considerations, and the need for personalized approaches tailored to the specific needs of this patient population. Existing literature offers valuable insights into various aspects of both sickle cell anemia and diabetes care, yet a comprehensive review focusing on the integrated approaches to managing these conditions, particularly in the pediatric population, is warranted. This review aims to fill this gap by synthesizing existing knowledge, highlighting research gaps, and providing a roadmap for developing integrated care strategies that address the unique challenges posed by the coexistence of sickle cell anemia and diabetes in children. By consolidating the available evidence and identifying areas for future exploration, this review aspires to contribute to the advancement of integrated care models that enhance the quality of life and health outcomes for pediatric patients grappling with the complexities of sickle cell anemia and diabetes.²⁴⁻⁴⁴

Metabolic Pathways and Enzyme Systems

The metabolic pathways and enzyme systems involved in the breakdown and utilization of medications for SCA and diabetes may intersect, leading to potential drug-drug interactions.⁴⁵ Understanding the pharmacokinetics of drugs used in the management of both conditions is essential. Healthcare providers must consider the shared pathways, such as those involving cytochrome P450 enzymes, to anticipate potential interactions and tailor medication regimens accordingly.

Anticoagulants and Antiplatelet Agents

Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. *Elite Journal of Health Science*, 2024; 2(2):1-9

Individuals with SCA often require anticoagulants or antiplatelet agents to manage complications such as vaso-occlusive crises, while those with diabetes may be prescribed similar medications for cardiovascular risk reduction. Balancing the risk of bleeding complications against the need for effective anticoagulation or antiplatelet therapy is crucial. A personalized approach, considering the overall health status and comorbidities of the individual, guides decision-making to optimize treatment outcomes.⁴⁶⁻⁵⁶

Pain Management and Analgesics

Chronic pain is a hallmark of SCA, often necessitating the use of opioids or other analgesics. Concurrently, individuals with diabetes may experience neuropathic pain, influencing the choice of analgesic medications. Striking a balance between effective pain management and avoiding potential interactions or exacerbation of side effects is paramount. Close monitoring for opioid-related complications, such as respiratory depression or sedation, is essential.⁵⁷⁻⁶²

Insulin Sensitizers and Hemoglobin S Modifiers

Medications aimed at improving insulin sensitivity, commonly prescribed in diabetes management, may interact with agents targeting hemoglobin S modification in SCA. Individualizing treatment plans by assessing the patient's overall health, glycemic control, and SCA-related complications guides the selection of medications. Regular monitoring ensures the efficacy and safety of the chosen regimens.⁶³⁻⁶⁸

Corticosteroids and Glucose Control

Corticosteroids, employed in the management of SCA complications, can influence glucose metabolism, potentially impacting glycemic control in individuals with diabetes. Close monitoring of blood glucose levels and adjusting diabetes medications when corticosteroids are initiated or adjusted helps maintain optimal glycemic control. Collaboration between hematologists and endocrinologists is crucial in these situations.⁶⁹⁻⁷⁶

Conclusion

The coexistence of sickle cell anemia and diabetes presents a multifaceted clinical challenge that demands a nuanced understanding of their individual complexities and the potential interactions between their treatment modalities. As the prevalence of individuals facing the dual burden of sickle cell anemia and diabetes continues to rise, healthcare providers must be equipped with comprehensive knowledge to navigate the complexities of drug interactions effectively. The insights gleaned from this exploration not only contribute to the current understanding of the interplay between sickle cell anemia and diabetes but also pave the way for evidence-based clinical practices. It is crucial for healthcare providers to consider the potential impact of drug interactions on disease progression, complications, and overall patient well-being. The refinement of treatment

Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science, 2024; 2(2):1-9

guidelines and the development of personalized therapeutic strategies are imperative to optimize care for individuals managing both conditions concurrently.

References

1. Jae G. The Anticipatory Politics of Sickle Cell Disease: An Examination of Policy, Practice, Care, and Innovation in the US and France. Columbia University; 2020.
2. Kohlscheen S, Bonig H, Modlich U. Promises and challenges in hematopoietic stem cell gene therapy. *Human Gene Therapy*. 2017;28(10):782-799.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. *Scholars Journal of Applied Medical Sciences*. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoietin in Sickle Cell Anaemia: A Review. *International Journal of Research Studies in Medical and Health Sciences*. 2020;5(2):22-28.
5. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2018;5(10):20-21.
6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. *J Biomed Sci*. 2022;11(10):84.
7. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. *International Research in Medical and Health Sciences*. 2023 Sep 11;6(4):12-17.
8. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. *European Journal of Biomedical and Pharmaceutical Sciences*. 2023;10((9): 72-75
9. Obeagu EI. An update on micro RNA in sickle cell disease. *Int J Adv Res Biol Sci*. 2018;5:157-8.
10. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. *J. Clinical and Laboratory Research*. 2021;3(5):2768-0487.
11. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP. Men's Essential roles in the Management of Sickle Cell Anemia. **NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES** 4(2):20-29.
<https://doi.org/10.59298/NIJSES/2023/10.3.1111>
12. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(10):41-.
13. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. *Journal of Clinical and Laboratory Research*. 2023;6(1):2768-0487.
14. Ifediora AC, Obeagu EI, Akahara IC, Eguzouwa UP. Prevalence of urinary tract infection in diabetic patients attending Umuahia health care facilities. *J Bio Innov*. 2016;5(1):68-82.
[links/5ae45fdfaca272ba507eb3c3/PREVALENCE-OF-URINARY-TRACT-INFECTION-IN-DIABETIC-PATIENTS-ATTENDING-UMUAHIA-HEALTH-CARE-FACILITIES.pdf](https://doi.org/10.59298/NIJSES/2023/10.3.1111).

Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. *Elite Journal of Health Science*, 2024; 2(2):1-9

15. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Ethanol root extract and fractions of *Sphenocentrum jollyanum* abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. *RPS Pharmacy and Pharmacology Reports*. 2023;2(2):rqad010.
16. Obeagu EI, Obeagu GU. Utilization of Antioxidants in the management of diabetes mellitus patients. *J Diabetes Clin Prac*. 2018;1(102):2. [links/5b6c2dec92851ca65053b74e/Utilization-of-Antioxidants-in-the-Management-of-Diabetes-Mellitus.pdf](https://doi.org/10.1007/s13306-018-0007-4).
17. Obeagu EI, Okoroiwu IL, Obeagu GU. Some haematological variables in insulin dependent diabetes mellitus patients in Imo state Nigeria. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2016;3(4):110-7. [links/5ae4abee458515760ac07a13/Some-haematological-variables-in-insulin-dependent-diabetes-mellitus-patients-in-Imo-state-Nigeria.pdf](https://doi.org/10.1007/s13306-016-0007-4).
18. Nwakulite A, Nwanjo HU, Nwosu DC, Obeagu EI. Evaluation of some trace elements in streptozotocin induced diabetic rats treated with *Moringa oleifera* leaf powder. *WJPMR*. 2020;6(12):15-8. [links/5fcb587092851c00f8516430/EVALUATION-OF-SOME-TRACE-ELEMENTS-IN-STREPTOZOCIN-INDUCED-DIABETIC-RATS-TREATED-WITH-MORINGA-OLEIFERA-LEAF-POWDER.pdf](https://doi.org/10.1007/s13306-020-0007-4).
19. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Ironi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. *International Journal of Research and Reports in Hematology*. 2022;5(2):113-121.
20. Okafor CJ, Yusuf SA, Mahmoud SA, Salum SS, Vargas SC, Mathew AE, Obeagu EI, Shaib HK, Iddi HA, Moh'd MS, Abdulrahman WS. Effect of Gender and Risk Factors in Complications of Type 2 Diabetic Mellitus among Patients Attending Diabetic Clinic in Mnazi Mmoja Hospital, Zanzibar. *Journal of Pharmaceutical Research International*. 2021;33(29B):67-78.
21. Galano ES, Yusuf SA, Ogbonnia SO, Ogundahunsi OA, Obeagu EI, Chukwuani U, Okafor CJ, Obianagha NF. Effect of Extracts of *Kigelia Africana* Fruit and *Sorghum Bicolor* Stalk on the Biochemical Parameters of Alloxan-Induced Diabetic Rats. *Journal of Pharmaceutical Research International*. 2021;33(25B):86-97.
22. Kama SC, Obeagu EI, Alo MN, Ochei KC, Ezugwu UM, Odo M, Ikpeke M, Ukeekwe CO, Amaeze AA. Incidence of Urinary Tract Infection among Diabetic Patients in Abakaliki Metropolis. *Journal of Pharmaceutical Research International*. 2020 Nov 17;32(28):117-121.
23. Nwakulite A, Obeagu EI, Eze R, Vincent CC, Chukwurah EF, Okafor CJ, Ibekwe AM, Adike CN, Chukwuani U, Ifionu BI. Evaluation of Catalase and Manganese in Type 2 Diabetic Patients in University of Port Harcourt Teaching Hospital. *Journal of Pharmaceutical Research International*. 2021;40-45.
24. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. *Int. J. Adv. Res. Biol. Sci*. 2023;10(3):81-89.

Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. *Elite Journal of Health Science*, 2024; 2(2):1-9

25. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. *Medicine*. 2023;102(48):e36462.
26. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. *Prevalence*.;5(100):0-5.
27. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. *Int. J. Curr. Res. Med. Sci.* 2018;4(3):26-32.
28. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. *Int. J. Curr. Res. Biol. Med.* 2023;1:1-7.
29. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2018;5(11):13-15.
30. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences*. 2023 Jun 10;6(2):10-13.
31. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(4):45-48.
32. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluation of Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
33. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. *blood*.;11:16.
34. Nwakulite A, Obeagu EI, Nwanjo HU, Nwosu DC, Nnatuanya IN, Vincent CC, Amaechi CO, Ochiabu O, Barbara MT, Ibekwe AM, Okafor CJ. Studies on Pancreatic Gene Expression in Diabetic Rats Treated with Moringa oleifera Leaf. *Journal of Pharmaceutical Research International*. 2021;33(28A):78-86.
35. Nwosu DC, Nwanjo HU, Obeagu EI, Ugwu GU, Ofor IB, Okeke A, Ochei KC, Kanu SN, Okpara KE. Evaluation of Lipoprotein A and Lipid Tetrad Index Pattern in Diabetic Patients Attending Metabolic Clinic in The Federal Medical Centre, Owerri, Imo State. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4 (3):126-140
36. Ezema GO, Omeh NY, Egbachukwu S, Agbo EC, Ikeyi AP, Obeagu EI. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia. *Asian Journal of Dental and Health Sciences*. 2023 Jun 15;3(2):32-36. <http://ajdhs.com/index.php/journal/article/view/43>.
37. Adu ME, Chukwuani U, Ezeor V, Okafor CJ, Amaechi CO, Vincent CC, Obeagu GU, Eze R, Nnatuanya IN, Nwosu DC, Nwanjo HU. Studies on molecular docking of moringa oleifera leaf phytochemical constituents on alpha glucosidase, alpha amylase and dipeptidyl peptidase. *Journal of Pharmaceutical Research International*. 2021;33(28A):239-345.
38. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Obeagu EI. Plasma Level of Macromolecules and Mathematical Calculation of Potential Energy in Type 2 Diabetic

Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. *Elite Journal of Health Science*, 2024; 2(2):1-9

- Individuals at NAUTH, Nnewi, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(47B):242-248.
39. Nwakulite A, Obeagu EI, Eze R, Ugochi VE, Vincent CC, Okafor CJ, Chukwurah EF, Unaeze BC, Amaechi CO, Okwuanaso CB, Chukwuani U. Estimation of Serum Glutathione Peroxidase in Streptozotocin Induced Diabetic Rat Treated with Bitter Leaf Extract. *Journal of Pharmaceutical Research International*. 2021;33(30B):200-206.
 40. Okoroiwu IL, Obeagu EI, San Miguel HG, Bote SA, Obeagu GU. Characterisation of HLA-DR antigen in patients type 1 diabetes mellitus in patient attending a tertiary hospital in Enugu, south-east Nigeria. *ACADEMIC JOURNAL*. 2023.
 41. Okoroiwu IL, Obeagu EI, Obeagu GU, Chikezie CC, Ezema GO. The prevalence of selected autoimmune diseases. *Int. J. Adv. Multidiscip. Res.* 2016;3(3):9-14.
 42. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF ENZYME ANTIOXIDANTS IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. *European Journal of Biomedical*. 2020;7(11):285-288.
 43. Nwosu DC, Nwanjo HU, Opara AU, Ofor IB, Obeagu EI, Ugwu GU, Ojiegbe GC, Nnorom RM, Nwokike GI, Okpara KE, Ochei KC. EVALUATION OF C-REACTIVE PROTEIN, SELENIUM AND GLYCOSYLATED HAEMOGLOBIN LEVELS IN DIABETIC PATIENTS ATTENDING METABOLIC CLINIC IN THE FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. **World Journal of Pharmacy and Pharmaceutical Sciences**, 2015; 4 (3):141-152.
https://www.academia.edu/download/38320132/NWOSU_EMMA_9.pdf.
 44. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF KIDNEY INJURY MOLECULE-1, CYSTATIN C, AND SERUM ELECTROLYTES IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. *Education*. 2002.
 45. Miceli G, Basso MG, Rizzo G, Pintus C, Tuttolomondo A. The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. *International Journal of Molecular Sciences*. 2022;23(23):14914.
 46. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. *Int J Curr Res Med Sci*. 2018;4(11):33-35.
 47. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. *Int J Hematol Blood Disord (Internet)* 2018 (cited 2021 Mar 4); 3. Available from: <https://symbiosisonlinepublishing.com/hematology/hematology25.php>. 2018 Sep.
 48. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. *APPLIED SCIENCES (NIJBAS)*. 2023;4(1).
 49. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. *British Journal of Medicine and Medical Research*. 2015;8(3):261-5.
 50. Obeagu EI. BURDEN OF CHRONIC OSTEOMYELITIS: REVIEW OF ASSOCIATED FACTORS. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):1-6.

Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. *Elite Journal of Health Science*, 2024; 2(2):1-9

51. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. *European Journal of Biomedical and Pharmaceutical sciences*. 2015;2(1):502-507.
52. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Anti-nutritional and gas chromatography-mass spectrometry (GC-MS) analysis of ethanol root extract and fractions of *Sphenocentrum jollyanum*. *RPS Pharmacy and Pharmacology Reports*. 2023;2(2): rqa007.
53. Obeagu EI, Scott GY, Amekpor F, Ugwu OP, Alum EU. Covid-19 Infection and Diabetes: A Current Issue. *International Journal of Innovative and Applied Research*. 2023;11(1):25-30.
54. Ugwu OP, Alum EU, Obeagu EI, Okon MB, Aja PM, Samson AO, Amusa MO, Adepoju AO. Effect of Ethanol leaf extract of *Chromolaena odorata* on lipid profile of streptozotocin induced diabetic wistar albino rats. *IAA Journal of Biological Sciences*. 2023;10(1):109-117.
55. Ifeanyi OE. Gestational Diabetes: Haematological Perspective. **South Asian Research Journal of Applied Medical Sciences**, 1 (2):41-42. DOI: 10.36346/SARJAMS.2019.v01i02.003
https://sarpublication.com/media/articles/SARJAMS_12_41-42.pdf.
56. Ogbu IS, Odeh EJ, Ifeanyichukwu OE, Ogbu C, Ude UA, Obeagu EI. Prevalence of prediabetes among first degree relatives of type 2 diabetes individuals in Abakaliki, Ebonyi State Nigeria. *Academic Journal of Health Sciences: Medicina Balear*. 2023;38(2):85-88.
<https://dialnet.unirioja.es/servlet/articulo?codigo=8845439>.
57. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickel Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
58. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickel Cell Anaemia: Current Burden in Africa. *International Journal of Innovative and Applied Research*. 2023;11(2):12-14.
59. Obeagu EI, Obeagu GU. Sickel Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences*. 2023 Jun 10; 6 (2): 10-13.
60. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *International Journal of Current Microbiology and Applied Sciences*. 2014;3(3):1000-1005.
61. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. *Int. J. Curr. Microbiol. App. Sci*. 2014;3(3):1000-1005.
62. Ifeanyi OE. An update on Diabetes Mellitus. *Int. J. Curr. Res. Med. Sci*. 2018;4(6):71-81. DOI: 10.22192/ijcrms.2018.04.06.012 [links/5b3b97a04585150d23f63e76/An-update-on-Diabetes-Mellitus.pdf](https://doi.org/10.22192/ijcrms.2018.04.06.012).

Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickel Cell Anemia and Diabetes. *Elite Journal of Health Science*, 2024; 2(2):1-9

63. Yan Q, Li D, Jia S, Yang J, Ma J. Novel gene-based therapeutic approaches for the management of hepatic complications in diabetes: Reviewing recent advances. *Journal of Diabetes and its Complications*. 2024;108688.
64. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obstetrics characteristics that effect the newborn outcomes. *Int. J. Adv. Res. Biol. Sci.* 2023;10(3):134-143.
65. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. *Int. J. Adv. Res. Biol. Sci.* 2023;10(2):160-163.
66. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *PARIPEX - INDIAN JOURNAL OF RESEARCH*, 2015; 4(6): 258-259
67. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. *Int. J. Curr. Microbiol. App. Sci.* 2014;3(3):1000-1005.
68. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. *Int. J. Curr. Microbiol. App. Sci.* 2014;3(3):1046-1050.
69. Wirngo FE, Lambert MN, Jeppesen PB. The physiological effects of dandelion (*Taraxacum officinale*) in type 2 diabetes. *The review of diabetic studies: RDS*. 2016;13(2-3):113.
70. Primavera R, Kevadiya BD, Swaminathan G, Wilson RJ, De Pascale A, Decuzzi P, Thakor AS. Emerging nano-and micro-technologies used in the treatment of type-1 diabetes. *Nanomaterials*. 2020;10(4):789.
71. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. *J Clin Med Res*. 2020; 2:1-4.
72. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. *Medicine*. 2024 Feb 9;103(6):e37127.
73. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. *Annals of Medicine and Surgery*. 2024;10-97.
74. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. *Medicine*. 2024 Jan 12;103(2):e36898.
75. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. *Elite Journal of Medicine*. 2024;2(1):47-56.
76. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. *Journal home page: <http://www.journalijar.com>*;12(01).

Citation: Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. *Elite Journal of Health Science*, 2024; 2(2):1-9